Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib.

Richard Tseng, PhD, Chen-Hsiung Yeh, Ph.D., Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D., Susan O’Brien, M.D., Francis Giles, M.D., Alison Hannah, Ph.D., Zeev Estrov, M.D., Michael Keating, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2922.

https://doi.org/10.1182/blood.V110.11.2922.2922

Published: 2007

Journal Articles

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Razelle Kurzrock, MD, Paul Hamlin, M.D., Anas Younes, M.D., David Hong, M.D., Michael Gordon, M.D., Matthew A. Spear, M.D., Michael A. Palladino, Ph.D., G. Kenneth Lloyd, Ph.D., Angie M. Longenecker, R.N., Saskia T.C. Neuteboom, Ph.D., Gillian F. Cropp, M.S., Alison Hannah, M.D., Carol Aghajanian, M.D.

Blood (2007) 110 (11): 4504.

https://doi.org/10.1182/blood.V110.11.4504.4504

Published: 2007

Journal Articles

A Phase 3 Randomized, Historically-Controlled Clinical Trial Investigating the Use of Defibrotide in the Treatment of Severe Veno-Occlusive Disease Post-SCT: A Novel Approach to the Validation of a Promising New Drug for the Treatment of a Life Threatening Disease.

Paul Richardson, Nancy Kernan, Marcie Tomblyn, Paul Martin, Sally Arai, Joel Brochstein, Eva Guinan, Gideon Steinbach, Elizabeth Nemecek, Ralph D’Agostino, Carolyn Revta, Alison Hannah, Massimo Iacobelli, Robert Soiffer

Blood (2007) 110 (11): 614.

https://doi.org/10.1182/blood.V110.11.614.614

Published: 2007

Journal Articles

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

Jeffrey Lancet, MD, Maria R. Baer, MD, Ivana Gojo, MD, M. Burton, M. Quinn, S.M. Tighe, Kapil Bhalla, MD, K. Kersey, S. Wells, Z. Zhong, PhD, B. Sadler, Maher Albitar, MD, Robert Johnson, MD, PhD, Alison Hannah, MBBS

Blood (2006) 108 (11): 1961.

https://doi.org/10.1182/blood.V108.11.1961.1961

Published: 2006

Journal Articles

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

Paul Richardson, MD, Asher Alban Chanan-Khan, MD, Sagar Lonial, MD, Amrita Krishnan, MD, Melissa Alsina, MD, Michael Carroll, MD, Karen Adler, G. Cropp, C. Mitsiades, MD, Robert Johnson, MD, PhD, Alison Hannah, MBBS, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 406.

https://doi.org/10.1182/blood.V108.11.406.406

Published: 2006

Journal Articles

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Sandhya Kumaraswamy, PhD, Que T. Lambert, MS, Kathy Rocha, BS, Purva Bali, MS, Warren Fiskus, PhD, Maria Balasis, BS, Michael Pranpat, MS, Sandhya Boyapalle, PhD, Alison Hannah, MD, Gary W. Reuther, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 4401.

https://doi.org/10.1182/blood.V106.11.4401.4401

Published: 2005

Journal Articles

Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells.

Angela Hatter, BS, Purva Bali, MS, Maria Balasis, BS, Warren Fiskus, PhD, Sandhya Boyapalle, PhD, Sandhya Kumaraswamy, PhD, Kathy Rocha, BS, Michael Pranpat, BS, Alison Hannah, MD, Eduardo Sotomayor, MD, PhD, Victoria Richon, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 2418.

https://doi.org/10.1182/blood.V106.11.2418.2418

Published: 2005

Journal Articles

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

Constantine S. Mitsiades, MD, PhD, Nicholas Mitsiades, MD, PhD, Melissa Rooney, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, PhD, Robert Johnson, MD, Alison Hannah, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2404.

https://doi.org/10.1182/blood.V104.11.2404.2404

Published: 2004

NARROW

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib.

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

A Phase 3 Randomized, Historically-Controlled Clinical Trial Investigating the Use of Defibrotide in the Treatment of Severe Veno-Occlusive Disease Post-SCT: A Novel Approach to the Validation of a Promising New Drug for the Treatment of a Life Threatening Disease.

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells.

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only